Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.05.2024 | Case report

Adalimumab/mycophenolate/prednisolone

Allergic reaction, lack of efficacy and rebound effect in the form of scleritis flare-up

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Dey S, et al. Tofacitinib in Refractory Scleritis: A Case Series. Mediterranean Journal of Rheumatology 34 : 367-371, No. 3, Jan 2023. Available from: URL: https://dx.doi.org/10.31138/mjr.20230828.ti Dey S, et al. Tofacitinib in Refractory Scleritis: A Case Series. Mediterranean Journal of Rheumatology 34 : 367-371, No. 3, Jan 2023. Available from: URL: https://dx.doi.org/10.31138/mjr.20230828.ti
Metadaten
Titel
Adalimumab/mycophenolate/prednisolone
Allergic reaction, lack of efficacy and rebound effect in the form of scleritis flare-up
Publikationsdatum
01.05.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-58916-9

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Rivaroxaban

Case report

Multiple drugs

Case report

Rituximab

Case report

Multiple drugs